University of California San Francisco

Mattis 144.jpg
Aras N. Mattis, MD, PhD

Assistant Professor, UCSF Department of Pathology

Address

513 Parnassus Avenue, HSW, #516
San Francisco, CA 94143
United States

Email: [email protected]
Phone: 415-514-3062

    Biography

    Aras N. Mattis, M.D., Ph.D., is a board-certified anatomic pathologist and clinical fellow in the Willenbring Lab. Dr. Mattis trained at the University of Illinois at Urbana-Champaign, earning both his doctorates, Biochemistry and Medicine, there in 2007. He continued his clinical training in Pathology at the University of California San Francisco completing residency in Anatomic Pathology with subsequent fellowship training in Surgical Pathology and Liver and gastrointestinal pathology under his clinical mentor, Dr. Linda Ferrell. Since 2010, he has worked in the Willenbring Lab, investigating the basic mechanisms of liver development and disease in the with a specific focus on liver metabolism and fatty liver disease as well as micro-RNA regulation of liver metabolism.

    Education

    Institution Degree Dept or School End Date
    University of Illinois Urbana-Champaign PhD Biochemistry 2007
    University of Illinois Urbana-Champaign MD Medicine 2007
    University of California Berkeley BA Molecular and Cell Biology - Genetics 1998

    Board Certifications

    American Board of Pathology, Anatomic Pathology

    Collaboration Interests

    I am interested in:

    • academic collaboration
    • academic senate committee service
    • companies and entrepreneurs
    • multicenter clinical research
    • press
    • prospective donors

    Clinical Expertise

    Liver and Gastrointestinal Pathology

    Program Affiliations

    UCSF Department of Pathology

    California Institute for Regenerative Medicine

    Grants and Funding

    • Establishing patient-derived iPSCs as a platform for discovery research in NAFLD | NIDDK | 2023-06-01 - 2028-05-30 | Role: MPI
    • Modeling and Characterization of NAFLD Phenotypes in a Severely Affected Family | NIH/NIDDK | 2024-02-01 - 2027-11-30 | Role: PI
    • Genetic Regulation of Nonalcoholic Fatty Liver Disease | NIH | 2021-06-08 - 2025-03-31 | Role: MPI
    • Regulation of Lipid Metabolism by miR-29a within Hepatocytes | NIH | 2013-09-01 - 2019-07-31 | Role: Principal Investigator

    Research Narrative

    Dr. Mattis' postdoctoral work includes the use of translational human biopsy material as well as patient-derived induced pluripotent stem cell reprogramming to hepatocytes. As a long-term goal, this work aims to develop a humanized liver mouse model of fatty liver disease. Aras is supported by the UCSF CIRM clinical fellow training grant and continues to work closely with the UCSF Department of Pathology as a clinical researcher.

    Research Interests

    Liver diseases including metabolic, pediatric, fibrotic, idiopathic, stem cell derived

    Hepatocytes for transplant and disease modeling, micro-RNA regulation of hepatocyte

    Development and metabolism, liver and gastrointestinal tumors, site-specific recombination.

    Publications

    MOST RECENT PUBLICATIONS FROM A TOTAL OF 56
    1. Metastatic colorectal adenocarcinoma tumor purity assessment from whole exome sequencing data.
      Tbeileh N, Timmerman L, Mattis AN, Toriguchi K, Kasai Y, Corvera C, Nakakura E, Hirose K, Donner DB, Warren RS, Karelehto E| | PubMed
    2. DNA content abnormality frequently develops in the right/proximal colon in patients with primary sclerosing cholangitis and inflammatory bowel disease and is highly predictive of subsequent detection of dysplasia.
      Zhang R, Rabinovitch PS, Mattis AN, Lauwers GY, Choi WT| | PubMed
    3. Self-Assembled Matrigel-Free iPSC-Derived Liver Organoids Demonstrate Wide-Ranging Highly Differentiated Liver Functions.
      Weng Y, Han S, Sekyi MT, Su T, Mattis AN, Chang TT| | PubMed
    4. Fundic Gland Polyps Lack DNA Content Abnormality Characteristic of Other Adenomatous Precursor Lesions in the Gastrointestinal Tract.
      Akanuma N, Rabinovitch PS, Mattis AN, Lauwers GY, Choi WT| | PubMed
    5. Transient expression of factor VIII and a chronic high-fat diet induces ER stress and late hepatocyte oncogenesis.
      Pierce GF, Mattis AN| | PubMed
    6. Targeting acid ceramidase ameliorates fibrosis in mouse models of non-alcoholic steatohepatitis.
      Yu A, Cable C, Sharma S, Shihan MH, Mattis AN, Mileva I, Hannun YA, Duwaerts CC, Chen JY| | PubMed
    7. Undifferentiated Induced Pluripotent Stem Cells as a Genetic Model for Nonalcoholic Fatty Liver Disease.
      Muñoz A, Theusch E, Kuang YL, Nalula G, Peaslee C, Dorlhiac G, Landry MP, Streets A, Krauss RM, Iribarren C, Mattis AN, Medina MW| | PubMed
    8. Clinical Application of Induced Hepatocyte-like Cells Produced from Mesenchymal Stromal Cells: A Literature Review.
      Bogliotti Y, Vander Roest M, Mattis AN, Gish RG, Peltz G, Anwyl R, Kivlighn S, Schuur ER| | PubMed
    9. Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A.
      Fong S, Yates B, Sihn CR, Mattis AN, Mitchell N, Liu S, Russell CB, Kim B, Lawal A, Rangarajan S, Lester W, Bunting S, Pierce GF, Pasi KJ, Wong WY| | PubMed
    10. Nonampullary Duodenal Adenomas in Familial Adenomatous Polyposis and Sporadic Patients Lack the DNA Content Abnormality That Is Characteristic of the Adenoma-Carcinoma Sequence Involved in the Development of Other Gastrointestinal Malignancies.
      Mohammed N, Rabinovitch PS, Wang D, Kovári BP, Mattis AN, Lauwers GY, Choi WT| | PubMed